In the treatment of secondary hyperparathyroidism in patients with CKD, the goal is to control parathyroid hormone levels in the early stages of disease, when parathyroid cells are still sensitive to physiological 1,25(OH)2D signaling. The gene discussed is PTH; the disease is chronic kidney disease.